177 related articles for article (PubMed ID: 25914960)
21. Uterine papillary serous carcinoma: patterns of failure and survival.
Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
[TBL] [Abstract][Full Text] [Related]
22. Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?
Velker V; D'Souza D; Prefontaine M; McGee J; Leung E
Int J Gynecol Cancer; 2016 Mar; 26(3):491-6. PubMed ID: 26825823
[TBL] [Abstract][Full Text] [Related]
23. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
24. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
[TBL] [Abstract][Full Text] [Related]
26. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
[TBL] [Abstract][Full Text] [Related]
27. Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: a Cooperation Task Force (CTF) Study.
Gadducci A; Cosio S; Landoni F; Maggino T; Zola P; Fuso L; Sartori E
Int J Gynecol Cancer; 2012 Oct; 22(8):1355-60. PubMed ID: 22976496
[TBL] [Abstract][Full Text] [Related]
28. Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma.
Zhang M; Yang TJ; Desai NB; DeLair D; Kollmeier MA; Makker V; Leitao MM; Abu-Rustum NR; Alektiar KM
Brachytherapy; 2019; 18(1):38-43. PubMed ID: 30316723
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
30. Factors prognostic of survival in advanced-stage uterine serous carcinoma.
Holman LL; Pal N; Iglesias DA; Soliman PT; Balakrishnan N; Klopp A; Broaddus RR; Fleming ND; Munsell MF; Lu KH; Westin SN
Gynecol Oncol; 2017 Jul; 146(1):27-33. PubMed ID: 28465008
[TBL] [Abstract][Full Text] [Related]
31. Population-based treatment and outcomes of Stage I uterine serous carcinoma.
van der Putten LJ; Hoskins P; Tinker A; Lim P; Aquino-Parsons C; Kwon JS
Gynecol Oncol; 2014 Jan; 132(1):61-4. PubMed ID: 24219983
[TBL] [Abstract][Full Text] [Related]
32. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
33. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.
Ayeni TA; Bakkum-Gamez JN; Mariani A; McGree ME; Weaver AL; Haddock MG; Keeney GL; Long HJ; Dowdy SC; Podratz KC
Gynecol Oncol; 2013 Jun; 129(3):478-85. PubMed ID: 23535279
[TBL] [Abstract][Full Text] [Related]
34. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
[TBL] [Abstract][Full Text] [Related]
35. Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population.
Corey L; Cote ML; Ruterbusch JJ; Vezina A; Winer I
Am J Obstet Gynecol; 2022 Apr; 226(4):541.e1-541.e13. PubMed ID: 34736911
[TBL] [Abstract][Full Text] [Related]
36. National Cancer Database Report of Lymphadenectomy Trends in Endometrial Cancer.
Cripe J; Handorf E; Brown J; Jain A; Rubin S; Mantia-Smaldone G
Int J Gynecol Cancer; 2017 Sep; 27(7):1408-1415. PubMed ID: 28525495
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study.
Zhou J; He ZY; Li FY; Sun JY; Lin HX; Wu SG; Chen QH
Oncotarget; 2016 Feb; 7(7):7952-9. PubMed ID: 26788911
[TBL] [Abstract][Full Text] [Related]
38. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
39. The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
Qu XM; Velker VM; Leung E; Kwon JS; Elshaikh MA; Kong I; Logie NA; Mendez LC; van der Putten LJ; Donovan EK; Munkarah AR; Wiebe EM; Parra-Herran C; Warner A; Louie AV; D'Souza DP
Gynecol Oncol; 2018 May; 149(2):283-290. PubMed ID: 29544706
[TBL] [Abstract][Full Text] [Related]
40. Primary Fallopian Tube Carcinoma: A Single-Institution Experience of 101 Cases: A Retrospective Study.
Bao L; Ding Y; Cai Q; Ning Y; Hu W; Xue X; Sun H; Hua K; Zhou X; Yi X
Int J Gynecol Cancer; 2016 Mar; 26(3):424-30. PubMed ID: 26825825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
